For virtually all patients with CF, treatment of chronic respiratory tract Pseudomonas aeruginosa with antibiotics delivered directly to the airway is a fundamental part of their regimen. But is a single inhaled antibiotic enough, or can Pseudomonas be better managed and patient outcomes improved by using multiple inhaled agents? And if so, what’s the best schedule for delivery? What does the evidence say?
In this Issue, Dr. Elliott Dasenbrook from the Cleveland Clinic analyzes what’s known about the use of multiple inhaled agents to treat chronic respiratory Pseudomonas aeruginosa in patients with CF.
Director, Cleveland Clinic
Adult Cystic Fibrosis Program
Cleveland, OH
Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD
Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD
Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD
1.0 hour Physicians
1.0 contact hour Nurses
Launch date: July 20, 2019
Expiration date: July 19, 2021